34 results about "Pirfenidone" patented technology

Disclosed herein is a method of treating Idiopathic Pulmonary Fibrosis (IPF). The method includes administering to a subject in need thereof the deuterium-enriched pirfenidone LYT-100 at a total daily dose from about 1650 mg to about 2500 mg.

The invention discloses a nano-drug delivery system for treating myocardial fibrosis as well as a preparation method and application of the nano-drug delivery system, and belongs to the technical field of biological medicines. According to the system, ZIF-8 is taken as a core carrier, the loading efficiency of pirfenidone is improved through high specific surface area and adjustable aperture, PCM myocardial targeting peptide is covalently coupled on the surface, and the limitation of tissue selectivity is broken through. Through coordination complexation, pi-pi conjugate accumulation and electrostatic interaction synergy, stable drug loading and microenvironment response release are guaranteed; a one-pot method and a carbodiimide method are adopted to wrap PFD and modify PCM on the surface of ZIF-8 to form a nano-drug delivery system; according to the system, the fibrosis process is intervened through multiple mechanisms, the enrichment degree and the acting time of the medicine at the diseased region are improved, the prepared medicine integrates the carrier structure advantage and the targeting peptide function, efficient medicine carrying, precise delivery and controllable release are achieved, a new scheme is provided for myocardial fibrosis treatment, and the system has wide application prospects.

The invention discloses a platinum (IV)-pirfenidone compound prodrug, a preparation method and microenvironment remodeling anti-tumor application, and belongs to the field of medical technology and drug synthesis. A series of molecules are characterized by being platinum prodrugs modified by pirfenidone derivatives. The synthesis method sequentially comprises the following steps: oxidizing platinum drugs, modifying hydroxyl groups, and introducing pirfenidone derivatives through esterification reaction. A series of molecules are reduced into Pt (II) drugs at the focus to kill cancer cells, and meanwhile, the released pirfenidone derivative can remodel the tumor microenvironment. The platinum prodrug disclosed by the invention not only has excellent cancer cell killing ability, but also is relatively low in drug resistance and excellent in safety, can trigger immunogenic cell death, and is a brand new chemotherapy-immunotherapy method. A series of molecules are convenient to synthesize, the preparation process is simple, and the amphipathicity is excellent, the anti-cancer capability is excellent, the drug resistance and toxicity are low, and the clinical application prospect is good.

A pharmaceutical composition for prevention or treatment of a disease or disorder characterized by chronic inflammation, associated with angiogenesis and fibrosis. The pharmaceutical composition includes a multi-target inhibitor, multi-phase modulator, or multi-kinase inhibitor, such as axitinib, nintedanib, pirfenidone, riociguat, sorafenib, sunitinib, lenvatinib, regorafenib, ponatinib, or pazopanib.

The invention provides a drug-loaded gelatin nanogel, a bionic nanogel, a preparation method of the drug-loaded gelatin nanogel, a preparation method of the bionic nanogel, a combined drug and application of the bionic nanogel, and belongs to the technical field of biological medicine. According to the invention, all-transretinoic acid, pirfenidone and gelatin react to form drug-loaded gelatin nanogel, and the drug-loaded gelatin nanogel can synergistically inhibit the activation of pancreatic stellate cells and block a fibrosis-promoting signal channel, so that the reversion of a pancreatic cancer fibrosis microenvironment is realized; meanwhile, the activated pancreatic stellate cell membrane is coated with the drug-loaded gelatin nanogel to construct the bionic nanogel, so that the bionic nanogel has active targeting property, and the delivery efficiency and the treatment effect of the drug are remarkably improved; and the drug-loaded gelatin nanogel, the bionic nanogel and the chemotherapeutic drug are combined for treating pancreatic cancer, so that a remarkable anti-tumor effect is achieved, and the combined treatment of the bionic nanogel and gemcitabine has a synergistic anti-tumor effect. The gel provided by the invention realizes effective regulation and control of a pancreatic cancer dense fibrosis microenvironment, and provides a feasible new strategy for treatment of pancreatic cancer.

The application discloses a pirfenidone nanosuspension inhalation solution for treating interstitial pneumonia and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The pirfenidone nanosuspension inhalation solution is composed of the following components in 1000ml: 8-12g of pirfenidone hydrochloride, 4-6g of polyethylene glycol-poly-L-histidine block copolymer, 45-55g of mannitol, 0.4-0.6g of antioxidant, 0.05mol / L of citric acid-sodium citrate buffer, and water for injection, wherein the amount of the citric acid-sodium citrate buffer is appropriate, and the water for injection is added to 1000ml. The application adopts a pulmonary targeted inhalation administration path of non-gastrointestinal absorption, so that the drug directly acts on the lung interstitial lesion part by bypassing the intestinal absorption link.

The application belongs to the technical field of medicines, and particularly relates to a pirfenidone co-crystal, a preparation method thereof, a pharmaceutical composition and application. The pirfenidone co-crystal is prepared from pirfenidone and a co-crystal ligand, and the co-crystal ligand is selected from one of heptanedioic acid, cinnamic acid and saccharin. The pirfenidone co-crystal can not only improve the effect of pirfenidone in relieving acute pancreatitis, but also improve the safety of pirfenidone.

The present invention concerns the compounds of formula (I)wherein R1, R2, R3, X, and Y are as described in the description, and their use as antagonists of the LPA1 receptor, in combination with one or more therapeutically active ingredients acting as anti-fibrotic agent(s); such as especially pirfenidone and / or nintedanib, in the prevention and / or treatment of fibrotic diseases. The invention further relates to pharmaceutical compositions comprising the compounds of formula (I) in combination with one or more therapeutically active ingredients acting as anti-fibrotic agent(s) such as pirfenidone or nintedanib.

The present application relates to the technical field of medicine, and particularly relates to an anti-pulmonary fibrosis prodrug compound and a preparation method and application thereof. The prodrug compound is a novel prodrug, and the structure comprises: a) an active drug unit selected from pirfenidone and nintedanib; b) a lung targeting unit selected from diphenyl chloroiodonium salt and a mimic thereof 521; and c) a linker unit which is a responsive linkage sensitive to a biomarker specifically overexpressed in a pulmonary fibrosis microenvironment. The prodrug is stable in the systemic circulation and has no activity or low activity, and can be actively targeted to a pulmonary fibrosis lesion; under the specific stimulation of the PFM, the linker is broken, and the original drug molecule is accurately released, so that the concentration of the drug in the lesion site is significantly increased, the toxic side effects caused by systemic exposure are reduced, and the anti-pulmonary fibrosis effect is enhanced.

Provided are alcohol amine derivatives, a preparation method therefor and the use thereof, and a drug for treating organ fibrosis or pulmonary inflammations caused by acute injury, belonging to the technical field of medicine. The alcohol amine derivatives have structures represented by formula R-1 or formula R-2 and are R-configuration compounds, and exhibit good therapeutic effects on organ fibrosis or pulmonary inflammations caused by acute injury. The results in the pharmacological embodiments show that the alcohol amine derivatives have excellent pharmaceutical effects both on pulmonary inflammations caused by acute injury and various types of organ fibrosis models, the pharmaceutical effects thereof being overall superior to that of S-configuration compounds and positive drugs Nintedanib and Pirfenidone.

This invention belongs to the field of biomedicine, specifically relating to the application of APOL2 (Apolipoprotein L2) inhibitors in the preparation of products for treating liver fibrosis. The inventors isolated a series of natural tetrodopane-type diterpenes from *Euphorbia pekinensis*, a plant in the Euphorbiaceae family. Anti-liver fibrosis-related activity tests on this series of diterpenes revealed that they significantly inhibited the expression of fibronectin, type I collagen, and α-smooth muscle actin in LX-2 cells. In animal studies, their therapeutic effect was superior to that of pirfenidone, a phase II clinical trial drug for treating liver fibrosis, and they showed no significant toxicity. Mechanistic studies showed that TD1 is an APOL2 inhibitor, and knocking out APOL2 protein in vivo can alleviate the progression of liver fibrosis. In summary, this series of tetrodopane-type diterpenes, especially TD1, shows promise as a candidate drug for treating liver fibrosis and provides a new target for researching novel drugs for treating liver fibrosis.

Disclosed herein are methods of stabilizing or improving lung function in subjects with an interstitial lung disease (ILD) by orally administering a daily amount of between 1600 mg and 2500 mg deupirfenidone. Also disclosed are methods of dose escalation for initial titration, methods of reducing the incidence of emerging adverse events, and methods of directly transitioning patients from other drugs to deupirfenidone without titration.

Disclosed herein are methods of stabilizing or improving lung function in subjects with idiopathic pulmonary fibrosis by orally administering a daily amount of between 1600 mg and 2500 mg deupirfenidone. Also disclosed are methods of dose escalation for initial titration, methods of reducing the incidence of emerging adverse events, and methods of directly transitioning patients from other drugs to deupirfenidone without titration.

The present application relates to the field of drug delivery technology and chronic kidney disease treatment, in particular, a kidney tissue targeted chronic kidney disease treatment drug nano delivery system, which solves the problems of poor targeting, low bioavailability, obvious side effects of existing chronic kidney disease treatment drugs, and insufficient responsiveness and poor safety of existing nano delivery systems. The system comprises a double-responsive nano carrier, an anti-kidney fibrosis drug and a targeting mediation layer. The double-responsive nano carrier is based on methoxy polyethylene glycol modified chitosan-polylactic acid copolymer, contains pH-sensitive hydrazone bonds and redox-sensitive disulfide bonds, and has a core-shell structure. The surface of the carrier is covalently connected with CD13 receptor affinity peptides, and is coated with a polylysine modified hyaluronic acid targeting mediation layer. The drug is pirfenidone or mycophenolate mofetil, which is covalently combined with the carrier through a disulfide bond. The system can realize precise enrichment of kidney lesions and double-responsive controlled drug release, improve the treatment effect, and reduce systemic and local toxicity.

The application provides a drug-loaded gelatin nanogel, a biomimetic nanogel and a preparation method and combined drug and use thereof, and belongs to the technical field of biological medicines.The application forms a drug-loaded gelatin nanogel by reacting all-trans retinoic acid with pirfenidone and gelatin, cooperatively inhibits the activation of pancreatic stellate cells and blocks the pro-fibrosis signal pathway, realizes the reversal of the fibrosis microenvironment of pancreatic cancer, coats the drug-loaded gelatin nanogel on the membrane of activated pancreatic stellate cells to construct a biomimetic nanogel, so that the biomimetic nanogel has active targeting, and the drug delivery efficiency and the treatment effect are significantly improved, and the drug-loaded gelatin nanogel, the biomimetic nanogel and a chemotherapeutic drug are combined to treat pancreatic cancer, have a significant anti-tumor effect, and the combined treatment of the biomimetic nanogel and gemcitabine has a synergistic anti-tumor effect.The gelatin realizes effective regulation of the dense fibrosis microenvironment of pancreatic cancer, and provides a new feasible strategy for the treatment of pancreatic cancer.

The invention belongs to the technical field of perampanel medicines, and particularly relates to a perampanel medicine composition and a preparation thereof. The perampanel pharmaceutical composition provided by the invention is composed of perampanel, Tween 80, a flavoring agent, a plasticizer and a film forming material, the pharmaceutical preparation is a perampanel oral soluble film, and the preparation method of the perampanel oral soluble film comprises the following steps: mixing perampanel, first Tween 80 and an ethanol aqueous solution, performing vacuum freeze drying, and crushing to obtain freeze-dried powder; heating the freeze-dried powder to 20-30 DEG C, performing vacuum freeze-drying, and crushing to obtain secondary freeze-dried powder; mixing second Tween 80 with water, adding the secondary freeze-dried powder, a flavoring agent, a plasticizer and a film-forming material, and stirring to obtain slurry; and carrying out vacuum defoaming on the slurry, then coating a base material with the slurry, and drying to obtain the perampanel oral soluble film. The oral soluble film provided by the invention has the advantages of excellent content uniformity and stability, high dissolution rate and good flexibility.

The present invention provides an oral sustained release solid formulation of pirfenidone relating to a formulation technique, comprising a sustained release formulation, the sustained release formulation containing a swelling and dissolving material, a plastic material and an adhesive material, the weight percentage of the swelling and dissolving material in the solid formulation being 10-25%, the weight percentage of the plastic material in the solid formulation being 10-25%, and the weight percentage of the adhesive material in the solid formulation being 1-8%. This solid formulation can be orally administered once a day, without any restriction on whether it can be administered before or after meals, and is effective immediately after administration and is released stably and effectively for 24 hours, thereby providing a pirfenidone product with significantly improved compliance and stable blood concentration.

The present invention relates to the field of pharmaceutical technology, and particularly, to a pirfenidone co-crystal and a method for preparing same, a pharmaceutical composition, and use thereof. The pirfenidone co-crystal provided in the present invention is prepared from pirfenidone and a co-crystal ligand selected from one of pimelic acid, cinnamic acid, and saccharin. The pirfenidone co-crystal provided in the present invention can not only improve the effect of pirfenidone in relieving acute pancreatitis, but also improve the safety of pirfenidone.

The present invention is applicable to the technical field of plant extraction and separation. Provided is a polysaccharide compound GLP-4 that has a clear molecular structure and has the effects of treating emphysema and pulmonary fibrosis and resisting tumors, which polysaccharide compound has a molecular formula of: (C162H270O135)n. Ganoderma is subjected to high-temperature and high-pressure extraction using an alkali solution, the resulting medicine residues are extracted, and then separation is performed by column chromatography to obtain the polysaccharide compound. The polysaccharide compound has a good water solubility, is easily absorbed by a human body, has better effects than pirfenidone in terms of the treatment of emphysema and pulmonary fibrosis, and also has efficacy in patients with advanced cancers (patients who have lost surgical condition, have a survival time of only three to six months, and still have chemotherapy condition). Especially when being used in combination with a chemotherapeutic drug, the polysaccharide compound can eliminate the toxic side effects caused by the chemotherapeutic drug in the human body, and can be used for controlling and reducing a tumor mass, and reducing and eliminating tumor cells, which effects are all supported by corresponding experimental data.

The invention relates to the field of cell therapy, in particular to application of NK cells in preparation of drugs for treating fibrosis diseases. The invention discloses application of NK (natural killer) cells in preparation of medicines for treating fibrosis diseases, and compared with nintedanib or pirfenidone, the NK cells have equivalent or even better effects in treatment of pulmonary fibrosis diseases, are higher in safety and do not cause side effects such as hepatotoxicity or renal toxicity. Also disclosed is a method of treating a subject suffering from a fibrotic disease by administering one or more NK cells to the subject.

The invention belongs to the field of medicines, and particularly relates to a perampanel long-acting controlled-release microsphere and a preparation method thereof. The invention aims to provide a long-acting and precise controlled-release perampanel microsphere which is prepared from an internal phase solution and an external phase solution by adopting a microfluidic method, wherein the internal phase solution comprises perampanel and a derivative thereof, PLGA (poly (lactic-co-glycolic acid)) and a good solvent of the perampanel and the derivative thereof; the external phase solution comprises a surfactant, a good solvent of the surfactant, and an internal phase solvent. According to the perampanel long-acting sustained and controlled release microspheres, the PLGA microspheres prepared through microfluidics are very uniform, can stably release drugs and have highly-stable repeatability and regularity, the perampanel-PLGA sustained release microspheres prepared through the microfluidics technology are combined with a customization strategy to be very promising, related microsphere products are also beneficial to transformation, and the perampanel long-acting sustained and controlled release microspheres are suitable for industrial production. The method is an effective solution.

The invention discloses application of AGGF1 as a drug target in treatment of idiopathic pulmonary fibrosis, and belongs to the technical field of drugs. Researches find that the angiogenic factor AGGF1 and polypeptide drugs thereof can effectively prevent and reverse idiopathic pulmonary fibrosis by inhibiting STING, NEMO and MAVS mediated DNA / RNA induction pathways, AGGF1 treatment depends on TRIM29, and the curative effect of AGGF1 is superior to that of a current standard treatment drug pirfenidone. The invention provides a new drug target and a novel therapy for the treatment of pulmonary fibrosis, especially idiopathic pulmonary fibrosis. The method disclosed by the invention is subsidized by a national key research and development plan project (2023YFA1800900).

The invention provides a crystal form of an N-(4-methylphenyl)-2-pyridone compound as well as a preparation method and application thereof, and particularly relates to application of the N-(4-methylphenyl)-2-pyridone compound in treatment of fibrosis, pneumoconiosis and fatty liver. The N-(4-methylphenyl)-2-pyridone compound crystal provided by the invention is relatively good in solubility, simple in preparation operation and good in repeatability, industrial production can be realized, the cost is reduced, and the production period is shortened. In addition, the crystal has lower phototoxicity, is obviously superior to a drug pirfenidone on the market, has excellent effects on treating fibrosis, pneumoconiosis and fatty liver, and has extremely high clinical application capability.

The present invention relates to novel sublingual compositions comprising an anti-fibrotic agent, as well as methods for their preparation. Wherein the composition comprising an anti- fibrotic agent such as pirfenidone or nintedanib and its analogs or pharmaceutically acceptable salts thereof. These novel sublingual compositions are intended for use in the treatment of fibrotic diseases, disorders, or conditions, such as idiopathic pulmonary fibrosis (IPF), and hypertensive diseases, disorders, or conditions such as pulmonary hypertension.

The invention discloses application of a medicine for treating renal fibrosis. The medicine YS434 disclosed by the invention shows an obvious renal fibrosis resisting effect in activated fiber cells and unilateral ureter obstruction mice, the effect is superior to that of a clinical medicine pirfenidone, and meanwhile, the medicine YS434 shows good biocompatibility and relatively high safety.

The invention relates to the technical field of pharmacology, in particular to application of ursodesoxychoberberine to preparation of a medicine for preventing and / or relieving and / or treating pulmonary fibrosis. The preparation for preventing and / or relieving and / or treating pulmonary fibrosis is characterized in that the preparation contains ursodesoxychoberberine. The preparation also comprises one or more of a pharmaceutically acceptable carrier, an auxiliary material and an excipient. Dosage forms of the preparation include but are not limited to capsules, particles, tablets, pills, spray, suppositories, aerosols, powder aerosols, patches, oral liquid or injection. The indexes of a low-dose group and a high-dose group of the ursodesoxychoberberine are remarkably improved, the effect of the high-dose group is the best, and particularly, the high-dose group of the ursodesoxychoberberine is remarkably superior to that of a pirfenidone (PFD) positive drug group in the aspect of improving the body weight of a mouse. The results show that the ursodesoxychoberberine has a good development prospect as a candidate drug for resisting pulmonary fibrosis.

The application discloses a pirfenidone derivative, a preparation method and application thereof. The pirfenidone derivative has a structural formula as shown in formula (I). In the formula (I), R1, R2, R3 and R4 can be the same or different, and are independently selected from any of the following groups: -CH3, -CH2OH, -CH2NH2, -CF3, -CH2NR5R6; R5 and R6 can be the same or different, and are independently selected from any of the following groups: -CH3, -C2H5. Compared with pirfenidone, the compound has a more optimal lung function improvement effect, and can meet the clinical requirement for treating pulmonary fibrosis (IPF).

The application belongs to the field of medicine, and particularly relates to a kind of pirfenidone long-acting controlled-release microspheres and a preparation method thereof.The purpose of the application is to provide a kind of long-acting and accurate controlled-release pirfenidone microspheres, which is prepared by microfluidic method using inner phase solution and outer phase solution.The inner phase solution comprises pirfenidone and its derivatives, PLGA and good solvent of the two;The outer phase solution comprises surfactant, good solvent of the surfactant and inner phase solvent.The pirfenidone long-acting controlled-release microspheres of the application are very uniform by using microfluidic preparation of PLGA microspheres, can smoothly release drug, have high stability, repeatability and regularity, the microfluidic technology for preparing pirfenidone-PLGA sustained-release microspheres proposed in the application is very promising in combination with customization strategy, and the related microsphere product is also beneficial to transformation, and is an effective solution.